TABLE 1

Magnitude and prevalence of IgG antibodies in cord blood

Assay/antigen tested (P. falciparum isolate)Sample size (no.)Mean (SD)/median (IQRa)No. (%) positive
Serology (fold increase in MFI over negative controls)
    LSA17824.7 (42.6)/4.7 (1.6–27.8)59 (75.6)
    CSP7829.5 (39.7)/11.4 (3.3–40.0)68 (87.2)
    PfCelTOS780.6 (1.4)/0.0 (0.0–0.0)15 (19.2)
    SE50780.6 (2.1)/0.0 (0.0–0.0)11 (14.1)
    SE36783.1 (6.9)/0.0 (0.0–2.6)34 (43.6)
    MSP142 (3D7)789.3 (11.9)/5.8 (0.0–12.0)58 (74.4)
    MSP142 (FVO)786.5 (9.5)/2.3 (0.0–10.6)46 (59.0)
    MSP142 (FUP)7812.2 (13.8)/6.8 (2.4–16.6)68 (87.2)
    EBA140788.7 (19.6)/1.7 (0.0–7.3)41 (52.6)
    EBA175789.9 (14.7)/3.7 (0.0–14.5)49 (62.8)
    EBA181789.6 (17.9)/2.7 (0.0–8.6)51 (65.4)
    AMA1 (3D7)7881.0 (46.4)/88.1 (48.4–101.6)76 (97.4)
    AMA1 (FVO)7896.7 (61.2)/113.9 (39.5–131.2)76 (97.4)
Variant surface antigen assay (geometric mean MFI)
    BFD 20067940.2 (56.4)/17.0 (11.0–46.0)42 (53.8)
    Msambweni 20067937.4 (40.9)/21.0 (13.0–44.0)54 (69.2)
    3D77924.2 (28.0)/13.5 (8.0–30.0)37 (47.4)
Growth and invasion inhibition assay (percent inhibition)
    Sial Dep IIA842.8 (7.5)/0.0 (0.0–0.0)12 (14.6)
    W2mef GIA8411.3 (15.6)/6.0 (0.0–19.6)31 (37.8)
    MSP1-19 IIA840.8 (2.7)/0.0 (0.0–0.0)5 (6.1)
    D10 GIA844.2 (8.5)/0.0 (0.0–4.6)18 (22.0)
  • a IQR, interquartile range.